Abstract
Intratumor heterogeneity exists in most, if not all, human solid tumors and is reflected by differences in morphology, antigenicity, chromosomal and biochemical markers, invasion, metastatic spread, as well as sensitivity to therapy. Heterogeneity may be the result of genetic and/or environmental mechanisms. To be assessed by immunohistochemistry, heterogeneity of tumor cells has to be expressed by antigenic changes, i.e. quantitative or qualitative differences in antigen expression, secretion or uptake. Consequently, presence and distribution of hormones, steroid hormone receptors (e.g., in mammary carcinomas), blood group antigens (e.g., in diverse carcinomas), and cytoskeletal components, particularly intermediate filament-associated proteins (e.g., in neoplasms of diverse origin), can indicate heterogeneity within a tumor.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
